Skip to main content

Table 1 Baseline characteristics of study subjects

From: Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais

Characteristics

Type of vaccine

 

First ChAdOx1 only or

first and second ChAdOx1

(n = 305) *

Second ChAdOx1 only

(n = 51) **

First and second CoronaVac/

third ChAdOx1

(n = 364) ***

Age, years (median, IQR)

51 (40–61)

39 (31–45)

39 (32.5–45)

Female, n (%)

167 (54.8)

20 (39.2)

50 (13.7)

Hormonal use, n (%)

18 (5.9)

3 (5.8)

29 (8)

Heparin exposure within 3 months, n (%)

2 (2.2)

0

1 (0.3)

Antithrombotics, n (%)

17 (5.6)

2 (3.9)

7 (1.9)

Family history of thrombosis, n (%)

11 (3.6)

0

7 (1.9)

  1. * 91 participants received only first dose of ChAdOx1 and 214 participants received both first and second dose of ChAdOx1.
  2. ** All participants previously exposed to the first dose of ChAdOx1 but did not participate in the study at that time
  3. *** Since these participants had first exposure to ChAdOx1, they were included in the study
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us